LABT News

Gainers Lakewood-Amedex (NASDAQ:LABT) shares moved upwards by 237.6% to $0.65 during Thursday's regular session. ADMA Biologics (NASDAQ:ADMA) stock increased by 25.62% to $13.16. The market value of theirread more...

Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock RedemptionPR NewswireSARASOTA, Fla., Nov. 5, 2026 SARASOTA, Fla., Nov. 5, 2026 /PRNewswire...

Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 20.4% to $0.34 during Wednesday's after-market session. Glaukos (NYSE:GKOS) stock rose 16.85% to $212.01. The company's market cap stands at $10.6 billion. Asread more...

From Insulin Management To Cell Replacement: The Diabetes Revolution Is Accelerating   New York, NY – October 7, 2026 – Diabetes cell therapy is moving into a very different phase. For years, the idea of replacing damaged or lost insulin-producing cells sounded more like a long-term scientific goal than a practical treatment strategy. That is […] The post Diabetes Cell Therapy Enters a New Era as Billion-Dollar Market Opportunity Takes Shape appeared first on Financial News Media.

Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin Compounds Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin...

Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences Lakewood-Amedex Biotherapeutics Announces Participation in October ConferencesPR NewswireSARASOTA, Fla., Oct. 1, 2026SARASOTA, Fla., Oct. 1, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT, the...

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) is heading deeper into the clinical stage with its lead antimicrobial candidate Nu-3, and fresh laboratory data are giving the company another potential catalyst as its Phase 2a trial gets underway.

Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot UlcersPR NewswireSARASOTA, Fla., Sept. 28, 2026 Lead...

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot UlcersPR NewswireSARASOTA, Fla., Sept. 24...